Description
Trade name:
Dolcil
Dolcyl
Composition:
Each tablet contains:
Glimepiride 6 mg
Properties:
A hypoglycemic drug for oral administration – a third-generation sulfonylurea derivative.
Glimepiride acts mainly by stimulating the secretion and release of insulin from the β-cells of the pancreas (pancreatic action). Like other sulfonylurea derivatives, this effect is based on an increase in the response of β-cells of the pancreas to physiological glucose stimulation, while the amount of secreted insulin is significantly less than with traditional drugs – sulfonylurea derivatives. The least stimulating effect of glimepiride on insulin secretion provides a lower risk of hypoglycemia. In addition to this, glimepiride has an extra-pancreatic effect – the ability to improve the sensitivity of peripheral tissues (muscle, fat) to the action of its own insulin, to reduce the absorption of insulin by the liver; inhibits the production of glucose in the liver. Glimepiride selectively inhibits cyclooxygenase and reduces the conversion of arachidonic acid to thromboxane A2, which promotes platelet aggregation, thus exerting an antithrombotic effect.
Glimepiride contributes to the normalization of lipids, reduces the level of malonic aldehyde in the blood, which leads to a significant decrease in lipid peroxidation, this contributes to the antiatherogenic effect of the drug.
Indications:
Treatment of type 2 diabetes mellitus with ineffectiveness of previously prescribed diet and exercise.
If glimepiride monotherapy is ineffective, it can be used in combination therapy with metformin or insulin.
Method of administration and dosage:
The average starting dosage is 1-2 mg once a day with breakfast.
The maximum starting dosage is 2 mg.
Contraindications:
– type 1 diabetes mellitus;
– diabetic ketoacidosis,
-diabetic precoma and coma;
– conditions accompanied by impaired absorption of food and the development of hypoglycemia (infectious diseases);
-leukopenia;
-severe liver dysfunction;
-severe renal dysfunction (including patients on hemodialysis);
-lactose intolerance, lactase deficiency, glucose-galactose malabsorption;
-pregnancy;
-lactation;
– hypersensitivity to glimepiride or to any inactive component of the drug, to other sulfonylurea derivatives or to sulfonamide drugs (risk of developing hypersensitivity reactions).
Precautionary measures:
Glimepiride should be taken at the recommended doses and at the appointed time. Errors in drug administration, such as skipping a dose, should never be corrected by taking a higher dose later. The doctor and the patient should discuss in advance the measures that should be taken in case of such errors (for example, skipping a drug or a meal) or in situations where it is impossible to take the next dose of the drug at the set time. The patient should immediately inform the doctor in case of taking too high a dose of the drug.
Side effects:
From the side of metabolism: in rare cases, hypoglycemic reactions may develop. From the side of the organ of vision: during treatment (especially at the beginning), transient visual impairments may occur due to changes in the concentration of glucose in the blood.
On the part of the digestive system: sometimes there may be nausea, vomiting, a feeling of heaviness or discomfort in the epigastrium.
Storage method:
Store at a temperature not exceeding 25 degrees.
Package:
The cardboard box contains 3 blisters of 10 tablets, paper instructions.
